[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009133310A3 - Association de la dronedarone avec au moins un diuretique, son application en therapeutique - Google Patents

Association de la dronedarone avec au moins un diuretique, son application en therapeutique Download PDF

Info

Publication number
WO2009133310A3
WO2009133310A3 PCT/FR2009/000450 FR2009000450W WO2009133310A3 WO 2009133310 A3 WO2009133310 A3 WO 2009133310A3 FR 2009000450 W FR2009000450 W FR 2009000450W WO 2009133310 A3 WO2009133310 A3 WO 2009133310A3
Authority
WO
WIPO (PCT)
Prior art keywords
dronedarone
diuretic
combination
therapeutic use
pharmaceutically acceptable
Prior art date
Application number
PCT/FR2009/000450
Other languages
English (en)
Other versions
WO2009133310A2 (fr
Inventor
Davide Radzik
Martin Van Eickels
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39684441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009133310(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2011504499A priority Critical patent/JP2011517694A/ja
Priority to EA201071203A priority patent/EA201071203A1/ru
Priority to CA2721560A priority patent/CA2721560A1/fr
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to EP09738344A priority patent/EP2280700A2/fr
Priority to BRPI0910559A priority patent/BRPI0910559A2/pt
Priority to MX2010011401A priority patent/MX2010011401A/es
Priority to CN2009801229250A priority patent/CN102065856A/zh
Priority to AU2009241966A priority patent/AU2009241966A1/en
Publication of WO2009133310A2 publication Critical patent/WO2009133310A2/fr
Publication of WO2009133310A3 publication Critical patent/WO2009133310A3/fr
Priority to TNP2010000443A priority patent/TN2010000443A1/fr
Priority to US12/903,374 priority patent/US20110136899A1/en
Priority to IL208749A priority patent/IL208749A0/en
Priority to ZA2010/07390A priority patent/ZA201007390B/en
Priority to MA33318A priority patent/MA32355B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Association de dronedarone ou un de ses sels pharmaceutiquement acceptables avec au moins un diurétique, son application en thérapeutique.
PCT/FR2009/000450 2008-04-17 2009-04-16 Association de la dronedarone avec au moins un diuretique, son application en therapeutique WO2009133310A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2009241966A AU2009241966A1 (en) 2008-04-17 2009-04-16 Combination of dronedarone with at least one diuretic, and therapeutic use thereof
BRPI0910559A BRPI0910559A2 (pt) 2008-04-17 2009-04-16 associação da dronedarona com pelo menos um diurético, e sua aplicação em terapêutica.
EA201071203A EA201071203A1 (ru) 2008-04-17 2009-04-16 Комбинациия дронедарона по меньшей мере с одним диуретиком, её применение в терапии
CA2721560A CA2721560A1 (fr) 2008-04-17 2009-04-16 Association de la dronedarone avec au moins un diuretique, son application en therapeutique
CN2009801229250A CN102065856A (zh) 2008-04-17 2009-04-16 决奈达隆与至少一种利尿药的组合及其治疗用途
EP09738344A EP2280700A2 (fr) 2008-04-17 2009-04-16 Association de la dronedarone avec au moins un diuretique, son application en therapeutique
MX2010011401A MX2010011401A (es) 2008-04-17 2009-04-16 Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica.
JP2011504499A JP2011517694A (ja) 2008-04-17 2009-04-16 ドロネダロンと少なくとも１つの利尿薬の組み合わせおよびこの治療的使用
TNP2010000443A TN2010000443A1 (en) 2009-04-16 2010-09-24 Combination of dronedarone with at least one diuretic, and therapeutic use thereof
US12/903,374 US20110136899A1 (en) 2008-04-17 2010-10-13 Combination of dronedarone with at least one diuretic, and therapeutic use thereof
IL208749A IL208749A0 (en) 2008-04-17 2010-10-14 Combination of dronedarone with at least one diuretic, and therapeutic use thereof
ZA2010/07390A ZA201007390B (en) 2008-04-17 2010-10-15 Combination of dronedarone with at least one diuretic, and therapeutic use thereof
MA33318A MA32355B1 (fr) 2008-04-17 2010-11-03 Association de la dronedarone avec au moins un diuretique, son application en therapeutique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR08/02128 2008-04-17
FR0802128A FR2930149B1 (fr) 2008-04-17 2008-04-17 Association de dronedarone avec au moins un diuretique, son application en therapeutique
US4599908P 2008-04-18 2008-04-18
US61/045,999 2008-04-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/903,374 Continuation US20110136899A1 (en) 2008-04-17 2010-10-13 Combination of dronedarone with at least one diuretic, and therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2009133310A2 WO2009133310A2 (fr) 2009-11-05
WO2009133310A3 true WO2009133310A3 (fr) 2009-12-23

Family

ID=39684441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/000450 WO2009133310A2 (fr) 2008-04-17 2009-04-16 Association de la dronedarone avec au moins un diuretique, son application en therapeutique

Country Status (26)

Country Link
US (1) US20110136899A1 (fr)
EP (1) EP2280700A2 (fr)
JP (1) JP2011517694A (fr)
KR (1) KR20110005245A (fr)
CN (1) CN102065856A (fr)
AR (1) AR071326A1 (fr)
AU (1) AU2009241966A1 (fr)
BR (1) BRPI0910559A2 (fr)
CA (1) CA2721560A1 (fr)
CL (1) CL2009000918A1 (fr)
CO (1) CO6300842A2 (fr)
CR (1) CR11735A (fr)
DO (1) DOP2010000308A (fr)
EA (1) EA201071203A1 (fr)
EC (1) ECSP10010552A (fr)
FR (1) FR2930149B1 (fr)
IL (1) IL208749A0 (fr)
MA (1) MA32355B1 (fr)
MX (1) MX2010011401A (fr)
NI (1) NI201000171A (fr)
PE (1) PE20091808A1 (fr)
SV (1) SV2010003702A (fr)
TW (1) TW200951117A (fr)
UY (1) UY31772A (fr)
WO (1) WO2009133310A2 (fr)
ZA (1) ZA201007390B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721489A1 (fr) * 2008-04-17 2009-12-03 Sanofi-Aventis Utilisation de dronedarone anti-arhythmique pour la prevention de l'hospitalisation causee par un trouble cardiovasculaire ou la mort subite attribuable a des causes vasculaires
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (fr) * 2008-04-29 2009-11-11 Sanofi-Aventis Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796617A1 (fr) * 1996-03-18 1997-09-24 Sanofi Utilisation de composés antiarythmiques dansla réduction de la mortalité post infarctus
FR2764800A1 (fr) * 1997-06-23 1998-12-24 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
WO2005105096A2 (fr) * 2004-04-15 2005-11-10 Bristol-Myers Squibb Company Composes heterocycliques fusionnes

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
FR2803846B1 (fr) * 2000-01-17 2002-04-05 Clariant France Sa 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation
FR2817864B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
FR2817865B1 (fr) * 2000-12-11 2005-02-18 Sanofi Synthelabo Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese
CA2433861A1 (fr) * 2000-12-27 2002-07-04 Genzyme Corporation Liberation controlee d'agents anti-arythmiques
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
DE10237819A1 (de) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20060093673A1 (en) * 2003-06-27 2006-05-04 Coury Arthur J Controlled release of anti-arrhythmic agents
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
US20090076137A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dronedarone
CA2721489A1 (fr) * 2008-04-17 2009-12-03 Sanofi-Aventis Utilisation de dronedarone anti-arhythmique pour la prevention de l'hospitalisation causee par un trouble cardiovasculaire ou la mort subite attribuable a des causes vasculaires
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (fr) * 2008-04-29 2009-11-11 Sanofi-Aventis Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone
EP2133075A1 (fr) * 2008-06-10 2009-12-16 Sanofi-Aventis Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention de la cardioversion
EP2133074A1 (fr) * 2008-06-10 2009-12-16 Sanofi-Aventis Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention de la fibrillation auriculaire permanente
EP2153830A1 (fr) * 2008-08-07 2010-02-17 Sanofi-Aventis Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention des accidents vasculaires cérébraux ou des accidents ischémiques transitoires
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) * 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796617A1 (fr) * 1996-03-18 1997-09-24 Sanofi Utilisation de composés antiarythmiques dansla réduction de la mortalité post infarctus
FR2764800A1 (fr) * 1997-06-23 1998-12-24 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
WO2005105096A2 (fr) * 2004-04-15 2005-11-10 Bristol-Myers Squibb Company Composes heterocycliques fusionnes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Diuretic", WIKIPEDIA, THE FREE ENCYCLOPEDIA, XP002553017, Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Diuretic#High_ceiling_loop_diuretics> [retrieved on 20080825] *

Also Published As

Publication number Publication date
AU2009241966A1 (en) 2009-11-05
MA32355B1 (fr) 2011-06-01
CR11735A (es) 2010-11-22
KR20110005245A (ko) 2011-01-17
IL208749A0 (en) 2010-12-30
SV2010003702A (es) 2011-03-04
MX2010011401A (es) 2011-03-02
FR2930149A1 (fr) 2009-10-23
AR071326A1 (es) 2010-06-09
EP2280700A2 (fr) 2011-02-09
EA201071203A1 (ru) 2011-06-30
ZA201007390B (en) 2012-01-25
BRPI0910559A2 (pt) 2015-09-22
CN102065856A (zh) 2011-05-18
NI201000171A (es) 2012-01-23
WO2009133310A2 (fr) 2009-11-05
TW200951117A (en) 2009-12-16
PE20091808A1 (es) 2009-12-03
CO6300842A2 (es) 2011-07-21
ECSP10010552A (es) 2010-11-30
UY31772A (es) 2009-12-14
CA2721560A1 (fr) 2009-11-05
FR2930149B1 (fr) 2011-02-18
CL2009000918A1 (es) 2010-06-11
JP2011517694A (ja) 2011-06-16
US20110136899A1 (en) 2011-06-09
DOP2010000308A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
USD624582S1 (en) Type font
WO2009144550A3 (fr) Utilisation de dronédarone dans un médicament utilisé pour prévenir un épisode cardiovasculaire menant à l’hospitalisation ou à la mort
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
WO2010060937A3 (fr) Combinaisons inhibitrices hsp90
MY154909A (en) Novel thiophene derivatives
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2012156296A8 (fr) Combinaison pharmaceutique destinée à être utilisée pour induire une perte de poids chez des patients atteints de diabète de type 2 et/ou pour empêcher une prise de poids chez des patients atteints de diabète de type 2
WO2010030598A3 (fr) Formulations pharmaceutiques comprenant du pemetrexed
BRPI0914802A2 (pt) Composto, pró-droga, medicamento, uso do composto ou uma pró-droga de mesmo.
WO2008070268A3 (fr) Compositions pharmaceutiques
WO2010118866A8 (fr) Composition contenant du trehalulose, sa preparation et son utilisation
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
BRPI1009392A2 (pt) &#34;formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica.&#34;
WO2011014825A3 (fr) Petites molécules anti-angiogéniques et procédés d&#39;utilisation
TW200942530A (en) Pyridine compounds
AP2012006292A0 (en) Topical use of hydroxytyrosol and derivatives for the prevention of HIV infection.
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2009144551A3 (fr) Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d’un médicament permettant la régulation du niveau de potassium dans le sang
WO2011069076A3 (fr) Formulation de donépézil à libération prolongée
WO2009133310A3 (fr) Association de la dronedarone avec au moins un diuretique, son application en therapeutique
PL2266619T3 (pl) Kompozycja farmaceutyczna na bazie środków chroniących wątrobę i środków prebiotycznych, ich wytwarzanie i zastosowanie
WO2009133455A3 (fr) Composition pharmaceutique de clopidogrel
AP2010005435A0 (en) 1,4-Naphthoquinone derivatives and therapeutic usethereof.
WO2008094054A3 (fr) Composés

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980122925.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09738344

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009738344

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3833/KOLNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 1001163

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2721560

Country of ref document: CA

Ref document number: 201011735

Country of ref document: CR

Ref document number: CR2010-011735

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20107023064

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 588624

Country of ref document: NZ

Ref document number: 2011504499

Country of ref document: JP

Ref document number: 10128306

Country of ref document: CO

Ref document number: 12010502338

Country of ref document: PH

Ref document number: MX/A/2010/011401

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009241966

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009241966

Country of ref document: AU

Date of ref document: 20090416

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2010000705

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 201071203

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201013632

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0910559

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101015